Group 1 - The Hang Seng Medical ETF managed by Harvest has shown active trading with a turnover of 10.03% and a transaction volume of 28.177 million yuan, indicating a vibrant market activity [3] - As of June 17, the latest scale of the Hang Seng Medical ETF reached 282 million yuan, marking a new high in nearly a year, with a significant increase of 13 million shares over the past week [3] - The net inflow of funds into the Hang Seng Medical ETF was 11.5645 million yuan, with a total of 14.6068 million yuan accumulated over the last five trading days [3] Group 2 - The Hang Seng Medical ETF has achieved a net value increase of 56.06% over the past year, ranking 15th out of 119 QDII equity funds, placing it in the top 12.61% [3] - The ETF's highest monthly return since inception was 23.84%, with the longest consecutive monthly gains being four months and a maximum cumulative increase of 35.08% [3] - The average monthly return during the rising months was 7.62% [3] Group 3 - The Hang Seng Medical ETF closely tracks the Hang Seng Healthcare Index, which reflects the overall performance of healthcare-related securities listed in Hong Kong [4] - The top ten weighted stocks in the Hang Seng Healthcare Index include Innovent Biologics, BeiGene, WuXi Biologics, CSPC Pharmaceutical Group, CanSino Biologics, China National Pharmaceutical Group, JD Health, 3SBio, Hansoh Pharmaceutical, and Zai Lab, collectively accounting for 58.13% of the index [4] Group 4 - The Hong Kong stock market has performed well this year, with institutional investors believing that external disturbances have limited impacts on the fundamentals, and corporate earnings remain resilient [6] - The combination of domestic growth stabilization policies and improved global liquidity conditions is expected to support the Hong Kong stock market, potentially leading to new highs [6] Group 5 - Wanlian Securities suggests focusing on opportunities in the innovative drug sector, emphasizing high technical barriers and rapid iteration in niche markets, while also considering companies' R&D and commercialization capabilities [7] - The outlook for domestic high-end equipment and key raw materials is promising, with a recovery in biotech financing expected to boost orders for CXO companies [7] - Investors without stock accounts can consider the Hang Seng Medical ETF Harvest Connect Fund (018433) to gain exposure to investment opportunities in the Hong Kong healthcare sector [7]